Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer
November 02, 2020 16:15 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office
October 05, 2020 07:00 ET
|
Trillium Therapeutics Inc.
Allowance received for the use of SIRPaFc to treat both hematologic and solid tumors (method of use patent)Allowance received for the TTI-622 composition of matter patent CAMBRIDGE, Mass., Oct. 05,...
Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors
September 18, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Closes US$150 Million Public Offering of Common Shares
September 16, 2020 16:05 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Announces Pricing of US$130 Million Public Offering of Common Shares
September 10, 2020 20:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Announces Proposed Public Offering of Common Shares
September 09, 2020 16:01 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.
September 08, 2020 16:56 ET
|
Trillium Therapeutics Inc.
Pfizer invests $25 million in Trillium common shares at $10.88 per shareJeff Settleman, PhD, Pfizer’s Chief Scientific Officer for Oncology Research & Development, to join Trillium Scientific...
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
September 08, 2020 16:05 ET
|
Trillium Therapeutics Inc.
TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.TTI-622 monotherapy shows 6/18...
Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results
August 12, 2020 07:00 ET
|
Trillium Therapeutics Inc.
TTI-621 study has progressed to the 2.0 mg/kg dosing levelTTI-622 showing early evidence of monotherapy activity$130.8 million of cash and investments as of June 30, 2020 CAMBRIDGE, Mass., Aug. ...
Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level
July 30, 2020 07:00 ET
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative...